The blood-brain barrier (BBB) is the tight endothelial layer that limits passage of large-molecule therapeutics into the central nervous system. Antibody, peptide, oligonucleotide, and gene-therapy CNS programs have historically been bottlenecked by BBB penetration. Two workhorse strategies dominate the 2026 delivery landscape: receptor-mediated transcytosis using transferrin receptor 1 (TfR1) shuttles, and focused-ultrasound temporary BBB opening (which paired with Sonothera's June 2026 $125 million financing for its ultrasound-aided genetic-medicine delivery platform).
July 2026 saw several deals reshape the delivery infrastructure. Lonza announced Thursday July 2 that it acquired rights to Nona Biosciences' TfR1 BBB technology and expanded its strategic collaboration with Nona; the platform uses single-domain VHH antibodies binding TfR1 and can deploy as IgG fusion or through Lonza's GlycoConnect bioconjugation. Preclinical data showed improved brain delivery versus a leading industry benchmark. Earlier in the summer, BioArctic signed a $30 million upfront, up to $770 million milestone BrainTransporter neurodegeneration collaboration with Eli Lilly (June 22 BIO 2026), extending Lilly's BBB platform bets alongside its Alzheimer's franchise.
Stories here cover BBB delivery platform deals, TfR1 and other receptor shuttle programs, and the CNS-therapeutic candidates that depend on them. See [[lonza]] and [[neurodegeneration]] for adjacent threads.
Voyager Therapeutics (NASDAQ: VYGR) presented six-month Good Laboratory Practice (GLP) toxicology data for VY1706, its investigational blood-brain-barrier-crossing AAV gene therapy targeting tau for Alzheimer's disease, in a Developing Topics late-breaking poster at AAIC 2026 in London on Monday July 13, 2026. The updated six-month data extends the prior three-month timepoint (64% reduction reported earlier this month): a single intravenous dose delivered sustained tau protein reduction up to 75% in key brain regions of non-human primates over six months. VY1706 was well tolerated with no adverse clinical pathology and no histopathological findings up to the highest dose tested. Notably, the program showed none of the typical AAV liver transaminase elevations at any dose level throughout six months, plasma neurofilament levels remained generally stable with no dose-related increases, and there were no cellular immune activations. Voyager received FDA Investigational New Drug (IND) clearance for VY1706, enabling initiation of a clinical trial in adults with early Alzheimer's disease with dosing expected in the second half of 2026.
Denali Therapeutics (NASDAQ: DNLI) co-founder and CEO Ryan Watts, PhD delivered the opening plenary address at the Alzheimer's Association International Conference (AAIC) 2026 in London on Sunday July 12, 2026, titled 'Accelerating the Discovery and Development of Medicines for Neurodegeneration.' The presentation covered advances in neurodegeneration biology, biomarkers for diagnosis and treatment-effect assessment, and biologic therapies designed to cross the blood-brain barrier. Denali's proprietary TransportVehicle (TV) platform leverages the body's iron transport system (transferrin receptor) to shuttle antibodies, enzymes, and oligonucleotides into the brain. AVLAYAH (tividenofusp alfa-eknm) received FDA accelerated approval March 2026 as the first FDA-approved biologic specifically designed to cross the blood-brain barrier, for the treatment of neurologic manifestations of Hunter syndrome in certain pediatric patients. DNL628 is enabled by Denali's Oligonucleotide TransportVehicle (OTV) and targets the MAPT gene encoding tau, with data expected 1H 2027; DNL921 is a separate Alzheimer's candidate with Phase 1/2b data expected in 2027. The plenary framing ties to the Lonza-Nona Biosciences TfR1 blood-brain-barrier deal covered in Saturday's digest.
Voyager Therapeutics (NASDAQ: VYGR) presented Developing Topics late-breaking poster data at AAIC 2026 in London (July 12-15) featuring VY1706, its investigational blood-brain-barrier-crossing AAV gene therapy targeting intracellular and extracellular tau for Alzheimer's disease. The 3-month GLP non-human primate toxicology study showed VY1706 was well tolerated at a single intravenous dose up to the highest level tested (5E13 vg/kg), with no adverse clinical pathology or histopathological findings. Tau protein was reduced up to 64% in key brain regions of non-human primates at 13 weeks following a single IV dose. Voyager received FDA Investigational New Drug (IND) clearance for VY1706 in H1 2026, enabling initiation of a clinical trial in adults with early Alzheimer's disease with dosing expected in the second half of 2026. The program extends the same BBB-delivery-plus-tau-reduction thesis that Denali's DNL628 OTV pursues via anti-tau ASO; both address the same therapeutic hypothesis through different modalities (AAV gene therapy vs. anti-sense oligonucleotide).
Lonza announced Thursday July 2, 2026 that it has acquired rights to Nona Biosciences' transferrin receptor 1 (TfR1) blood-brain barrier (BBB) technology and expanded its strategic collaboration with Nona to develop next-generation BBB delivery platforms. The technology uses single-domain VHH antibodies that bind TfR1, a receptor expressed on the cells lining the blood-brain barrier, to shuttle attached payloads into the brain. The platform can deploy as an immunoglobulin G (IgG) fusion or through conjugation with therapeutic molecules using Lonza's GlycoConnect bioconjugation technology. Preclinical data show that Nona's TfR1-binding VHH improved brain delivery versus a leading industry benchmark in a relevant transgenic model. Financial terms were not disclosed. Under the agreement, Lonza will immediately make the technology available to CNS drug developers while continuing to collaborate with Nona on future BBB platforms. The deal fits Lonza's CDMO-facing strategy of combining GS Gene Expression System capabilities with GlycoConnect chemistry to give customers new tools for CNS therapeutic candidates — including peptide-and-conjugate CNS programs that have historically been limited by BBB penetration.
A 2026 review published in Cell and Tissue Research (Springer Nature) synthesized the current understanding of brain peptides in Alzheimer's disease pathophysiology and therapeutic development. The review's central organizing distinction is between pathogenic peptide species (amyloid-β oligomers, tau-derived fragments) that drive neuronal dysfunction and endogenous neuropeptides that exert neuroprotective effects: neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), and pituitary adenylate cyclase-activating peptide (PACAP) are the three best-characterized protective classes. Adjacent April 2026 IJMS review covers the same neuropeptide neuroprotection thesis with broader Parkinson's-disease applicability. Advances in peptide chemistry are enabling two distinct therapeutic strategies: aggregation inhibitors that prevent amyloid-β oligomerization, and receptor-selective neuropeptide analogues that recapitulate endogenous NPY/VIP/PACAP signaling with improved blood-brain-barrier penetration. The peptide-neurodegeneration thread runs parallel to the BioArctic-Lilly $800 million BrainTransporter pact (June 23, peptide-delivery focus), Insilico-SK Biopharm $2.5B AI-neuroimmune deal (June 22 BIO 2026 opening), and the NVG-291 PTPσ inhibitor that NervGen is preparing for Phase 3 in chronic SCI mid-2026.
BioArctic (Nasdaq Stockholm: BIOA b) announced on June 22, 2026 a research and collaboration agreement with Eli Lilly combining BioArctic's proprietary BrainTransporter technology — transferrin-receptor-mediated active transport across the blood-brain barrier — with an undisclosed Lilly proprietary molecule in neurodegeneration. BioArctic receives $30M upfront, eligibility for milestone payments up to $770M (total potential value ~$800M), plus tiered mid-single-digit royalties on global net sales. BioArctic will generate the new drug candidate combining the technology with Lilly's molecule; Lilly assumes full global development and commercialization responsibility. This is BioArctic's fourth BrainTransporter partnership, after collaborations with Bristol Myers Squibb (Alzheimer's), AbbVie, and an undisclosed partner. The deal signals continued big-pharma demand for blood-brain-barrier delivery platforms as neurodegeneration competition intensifies post-leqembi.
Sapience Therapeutics' May 21 ASCO 2026 data update on lucicebtide (ST101) — a first-in-class C/EBPβ peptide antagonist — included a specific data point worth surfacing for the Tuesday cycle. In the Phase 2 Window-of-Opportunity study (n=9 evaluable as of April 27 data cutoff), patients with newly diagnosed glioblastoma (ndGBM) treated with lucicebtide plus standard-of-care chemoradiation achieved a projected median progression-free survival of 28.4 months — meaningfully exceeding the 4.0-6.9 month historic benchmark range. Six of nine patients remain alive past 22.3 months against a historical median OS range of 14.6-17.0 months. Median overall survival has not yet been reached. Lucicebtide crossed the blood-brain barrier with confirmed tumor uptake and target engagement via negative enrichment of the C/EBPβ regulon in tumor and myeloid cells. The poster session is scheduled for Monday June 1.